تريتايس كومب ٢٫٥ ملغم/١٢٫٥ ملغ إسرائيل - العربية - Ministry of Health

تريتايس كومب ٢٫٥ ملغم/١٢٫٥ ملغ

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

نورميتن ١٠٠ إسرائيل - العربية - Ministry of Health

نورميتن ١٠٠

teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

نورميتن ٥٠ إسرائيل - العربية - Ministry of Health

نورميتن ٥٠

abic ltd. - atenolol 50 mg - tablets - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

دوﻧپيزيل تيڤع ١٠ ملغ إسرائيل - العربية - Ministry of Health

دوﻧپيزيل تيڤع ١٠ ملغ

teva pharmaceutical indust.ltd - donepezil hydrochloride 5 mg - tablets - donepezil - treatment of mild to moderately severe alzheimer's dementia.

نورميتن ٢٥ إسرائيل - العربية - Ministry of Health

نورميتن ٢٥

abic ltd. - atenolol 25 mg - tablets - beta blocking agents, selective - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction.

ليتروزول تيڤع إسرائيل - العربية - Ministry of Health

ليتروزول تيڤع

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.